Rocamora F, Peralta A, Shin S, Sorrentino J, Wu M, Toth E
Biotechnol Adv. 2023; 67:108206.
PMID: 37354999
PMC: 11168894.
DOI: 10.1016/j.biotechadv.2023.108206.
Narimatsu Y, Bull C, Chen Y, Wandall H, Yang Z, Clausen H
J Biol Chem. 2021; 296:100448.
PMID: 33617880
PMC: 8042171.
DOI: 10.1016/j.jbc.2021.100448.
Feng W, Liu J, Ao H, Yue S, Peng C
Theranostics. 2020; 10(24):11278-11301.
PMID: 33042283
PMC: 7532689.
DOI: 10.7150/thno.47289.
Safary A, Akbarzadeh Khiavi M, Omidi Y, Rafi M
Cell Mol Life Sci. 2019; 76(17):3363-3381.
PMID: 31101939
PMC: 11105648.
DOI: 10.1007/s00018-019-03135-z.
Solomon M, Muro S
Adv Drug Deliv Rev. 2017; 118:109-134.
PMID: 28502768
PMC: 5828774.
DOI: 10.1016/j.addr.2017.05.004.
Subcellular Trafficking of Mammalian Lysosomal Proteins: An Extended View.
Staudt C, Puissant E, Boonen M
Int J Mol Sci. 2016; 18(1).
PMID: 28036022
PMC: 5297682.
DOI: 10.3390/ijms18010047.
Monocytes/Macrophages Upregulate the Hyaluronidase HYAL1 and Adapt Its Subcellular Trafficking to Promote Extracellular Residency upon Differentiation into Osteoclasts.
Puissant E, Boonen M
PLoS One. 2016; 11(10):e0165004.
PMID: 27755597
PMC: 5068775.
DOI: 10.1371/journal.pone.0165004.
CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings.
Burrow T, Sun Y, Prada C, Bailey L, Zhang W, Brewer A
Mol Genet Metab. 2014; 114(2):233-241.
PMID: 25219293
PMC: 4312736.
DOI: 10.1016/j.ymgme.2014.08.011.
Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.
Muro S
Drug Deliv Transl Res. 2014; 2(3):169-86.
PMID: 24688886
PMC: 3969788.
DOI: 10.1007/s13346-012-0072-4.
Gene therapy for the neurological manifestations in lysosomal storage disorders.
Cheng S
J Lipid Res. 2014; 55(9):1827-38.
PMID: 24683200
PMC: 4617364.
DOI: 10.1194/jlr.R047175.
A Hitchhiker's guide to the blood-brain barrier: in trans delivery of a therapeutic enzyme.
Sands M
Mol Ther. 2014; 22(3):483-484.
PMID: 24584077
PMC: 3944337.
DOI: 10.1038/mt.2014.12.
High resolution crystal structure of human β-glucuronidase reveals structural basis of lysosome targeting.
Hassan M, Waheed A, Grubb J, Klei H, Korolev S, Sly W
PLoS One. 2013; 8(11):e79687.
PMID: 24260279
PMC: 3834196.
DOI: 10.1371/journal.pone.0079687.
The liver parenchymal cells of rainbow trout (Salmo gairdneri) endocytose mannose-terminated glycoproteins.
Fritzvold R, Dannevig B, Berg T
Fish Physiol Biochem. 2013; 6(6):367-75.
PMID: 24221689
DOI: 10.1007/BF01875606.
Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII.
Huynh H, Grubb J, Vogler C, Sly W
Proc Natl Acad Sci U S A. 2012; 109(42):17022-7.
PMID: 23027951
PMC: 3479451.
DOI: 10.1073/pnas.1214779109.
Imiglucerase in the treatment of Gaucher disease: a history and perspective.
Deegan P, Cox T
Drug Des Devel Ther. 2012; 6:81-106.
PMID: 22563238
PMC: 3340106.
DOI: 10.2147/DDDT.S14395.
Pathology and current treatment of neurodegenerative sphingolipidoses.
Eckhardt M
Neuromolecular Med. 2010; 12(4):362-82.
PMID: 20730629
DOI: 10.1007/s12017-010-8133-7.
New strategies for enzyme replacement therapy for lysosomal storage diseases.
Grubb J, Vogler C, Sly W
Rejuvenation Res. 2010; 13(2-3):229-36.
PMID: 20345279
PMC: 2946059.
DOI: 10.1089/rej.2009.0920.
Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome.
Tomatsu S, Montano A, Dung V, Ohashi A, Oikawa H, Oguma T
Mol Ther. 2010; 18(6):1094-102.
PMID: 20332769
PMC: 2889747.
DOI: 10.1038/mt.2010.32.
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.
Muro S
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 2(2):189-204.
PMID: 20112244
PMC: 4002210.
DOI: 10.1002/wnan.73.
Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.
Sola R, Griebenow K
BioDrugs. 2010; 24(1):9-21.
PMID: 20055529
PMC: 2805475.
DOI: 10.2165/11530550-000000000-00000.
